Novavax Stock News

The vaccine supplier is forecasting revenues of up to $US5 billion now that it’s selling doses to Australia and the world and expects to launch a new trial of its combined flu and coronavirus vaccine later this year.

Covid Response Minister Chris Hipkins has confirmed Novavax has been approved for use for adults and doses will arrive this month.

New Zealanders will soon be able to access a third type of COVID-19 vaccine, COVID-19 Response Minister Chris Hipkins said today. “The Novavax

Novavax (NVAX) delivered earnings and revenue surprises of -681.82% and 42.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

COVID-19 Response Minister Chris Hipkins has confirmed Novavax has been approved for use for adults in New Zealand.

LONDON (REUTERS) – Novavax said on Monday (Feb 28) that an extended analysis of a late-stage study conducted in the United Kingdom showed that its Covid-19 vaccine provided long-term protection… The post Novavax’s Covid-19 vaccine shows long-term efficacy in UK trial appeared first on Nigeria''s Top News Site .

Novavax press release (NVAX): Q4 Non-GAAP EPS of -$11.18 misses by $9.38.Revenue of $222.2M (-20.5% Y/Y) misses by $109.59M.Shares -1.04% AHFull year 2022 total revenue guidance…

The Covid-19 vaccine maker Novavax expects revenue of between $4 billion and $5 billion in 2022, That compares with $1.1 billion for 2021.

"The vaccine offers protection against symptomatic and asymptomatic COVID-19 infection which may both interrupt virus transmission and prevent COVID-19 disease," said Gregory Glenn, president of research and development. "Additionally, we are encouraged to see that our COVID-19 vaccine maintains a high level of durable efficacy and continues to exhibit a reassuring safety profile in this extended timeframe." Earlier this month, Britain approved the two-dose COVID-19 vaccine for use in adults.

GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ -- NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and…

Novavax Inc said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccine provided long-term protection against the coronavirus. The protein-based vaccine, NVX-CoV2373, continued to provide protection and maintained overall efficacy of 82.7% over a six-month period, the company said. Additionally, vaccine efficacy of 82.5% […]

- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md. , March 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today shared extended analysis from its pivotal Phase 3 clinical trial conducted in the United Kingdom (UK), showing that a high level of efficacy for its protein-based COVID-19 vaccine, NVX-CoV2373, was maintained over a 6-month period of surveillance. Additionally, the analysis showed vaccine efficacy of 82.5% (95% CI: 75.0, 87.7) in protection against all COVID-19 infection – both symptomatic and asymptomatic – as measured by PCR+ or anti-N seroconversion. "These data have two implications for NVX-CoV2373. Importantly, the vaccine offers protection against symptomatic and asymptomatic COVID-19 infection which may both interrupt virus transmission and prevent COVID-19 disease," said Gregory M.

China’s NIO is planning a secondary listing in Hong Kong; Results are due from Novavax.